argenex SE (NASDAQ:ARGX) Stock Has Consensus Price Target of $1,145.00

Shares of argenex SE (NASDAQ:ARGX) have earned a consensus recommendation of “Moderate Buy” from the twenty-eight research firms that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation, twenty-one have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $1,158.76.

A number of brokerages have commented on ARGX. Wells Fargo & Company decreased their price target on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a research note on Friday, October 23rd. DZ Bank reissued a “buy” rating on shares of argenex in a research note on Friday, October 9th. HC Wainwright raised their target price on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Sanford C. Bernstein restated a “buy” rating on shares of argenex in a report on Thursday, October 8th. Finally, Truist Financial lifted their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th.

Institutional Investors Weigh In On argenex

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in shares of argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares during the period. First Trust Advisors LP increased its position in argenex by 98.9% during the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after buying an additional 53,293 shares in the last quarter. Squarepoint Ops LLC raised its stake in argenex by 314.8% during the second quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock valued at $54,182,000 after buying an additional 44,321 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in argenex in the second quarter worth $27,584,000. Finally, Hsbc Holdings PLC bought a new stake in argenex in the first quarter worth $14,882,000. Institutional investors own 60.32% of the company’s stock.

argenex Stock Down 0.6%

argenex stock opened at $892.87 on Thursday. The firm has a fifty day simple moving average of $943.61 and a two-hundred day simple moving average of $854.82. argenex has a twelve month low of $661.85 and a twelve month high of $1,072.75. The company has a market capitalization of $56.15 billion, a PE ratio of 31.15, a P/E/G ratio of 0.82 and a beta of 0.44.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. As a group, equities analysts expect that argenex will post 28.63 earnings per share for the current fiscal year.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.